🇺🇸 FDA
Pipeline program

Ivonescimab

26-021

Phase 2 small_molecule active

Quick answer

Ivonescimab for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Summit Therapeutics with 3 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials